The truth about the new class of Alzheimer’s drugs

You May Be Interested In:New Trump tariffs put Brazil in crosshairs ahead of August 1 deadline


Illustration of amyloid plaques (orange) among brain cells

Science Photo Library/Alamy

In early July, the US Food and Drug Administration (FDA) approved a treatment called donanemab for people with early-stage Alzheimer’s disease. It is the second drug shown to slow the condition’s progression, and the third FDA-authorised medication that clears the amyloid proteins that accumulate in the brains of people with Alzheimer’s.

The FDA’s approval of three new drugs – donanemab, lecanemab and aducanumab – in just over three years has led some to declare a leap forward in Alzheimer’s disease treatment. Japan, South Korea, China,…

share Paylaş facebook pinterest whatsapp x print

Similar Content

Can CoQ10 Supplements Really Help With Your Fertility?
Can CoQ10 Supplements Really Help With Your Fertility?
New Scientist. Science news and long reads from expert journalists, covering developments in science, technology, health and the environment on the website and the magazine.
Common chemical in drinking water hasn’t been tested for safety
women exercising at the gym
Weight-loss drugs lower impulse to eat – and perhaps to exercise too
Are ‘Broken Skin Barriers’ a Real Thing?
Are ‘Broken Skin Barriers’ a Real Thing?
The Best Hair and Makeup from the Grammys 2025 Red Carpet
The Best Hair and Makeup from the Grammys 2025 Red Carpet
How to Get Over a Broken Heart, According to Relationship Experts
How to Get Over a Broken Heart, According to Relationship Experts
Streamline News | © 2024 | News